In ER+ MCF7 breast cancer cells, the pharmacological inhibition of MAPK/MEK/ERK or PI3K/AKT signaling had no effect on dormancy markers, while a STAT3 inhibitor reduced pro-dormancy genes [73]. The gene discussed is STAT3; the disease is breast carcinoma.